within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AC56_AcetylsalicylicAcidCombinationsWithProtonPumpInhibitors;

model AcetylsalicylicAcidCombinationsWithProtonPumpInhibitors
  extends Pharmacolibrary.Drugs.ATC.B.B01AC56;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>B01AC56</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Acetylsalicylic acid (ASA), commonly known as aspirin, is an antiplatelet medication used widely for secondary prevention of cardiovascular events (such as heart attack or stroke). It is sometimes combined with proton pump inhibitors (PPIs) to reduce the risk of gastrointestinal side effects, particularly gastrointestinal bleeding, in patients requiring long-term ASA therapy. This combination is approved and used today for cardiovascular protection in at-risk populations.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are estimated for healthy adults administered oral fixed-dose acetylsalicylic acid/proton pump inhibitor combination.</p><h4>References</h4><ol><li><p>Abrignani, MG, et al., &amp; Abrignani, V (2023). Proton pump inhibitors and gastroprotection in patients treated with antithrombotic drugs: A cardiologic point of view. <i>World journal of cardiology</i> 15(8) 375–394. DOI:<a href=&quot;https://doi.org/10.4330/wjc.v15.i8.375&quot;>10.4330/wjc.v15.i8.375</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37771340/&quot;>https://pubmed.ncbi.nlm.nih.gov/37771340</a></p></li><li><p>Echizen, H (2016). The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. <i>Clinical pharmacokinetics</i> 55(4) 409–418. DOI:<a href=&quot;https://doi.org/10.1007/s40262-015-0326-7&quot;>10.1007/s40262-015-0326-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26369775/&quot;>https://pubmed.ncbi.nlm.nih.gov/26369775</a></p></li><li><p>Jourdi, G, et al., &amp; Gaussem, P (2024). An update on oral antiplatelet drug interactions with proton pump inhibitors: what are the risks?. <i>Expert opinion on drug metabolism &amp; toxicology</i> 20(8) 749–764. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2024.2378888&quot;>10.1080/17425255.2024.2378888</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38980768/&quot;>https://pubmed.ncbi.nlm.nih.gov/38980768</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end AcetylsalicylicAcidCombinationsWithProtonPumpInhibitors;
